Skip to main content
Download PDF

The emerging role of Cardiovascular Magnetic Resonance in the evaluation of hypertensive heart disease

BMC Cardiovascular Disorders volume 17, Article number: 132 (2017) Cite this article

Abstract

Background

Arterial hypertension is the commonest cause of cardiovascular death. It may lead to hypertensive heart disease (HHD), including heart failure (HF), ischemic heart disease (IHD) and left ventricular hypertrophy (LVH).

Main body

According to the 2007 ESH/ESC guidelines, the recommended imaging technique is echocardiography (echo), when a more sensitive detection of LVH than that provided by ECG, is needed. Cardiovascular Magnetic Resonance (CMR), a non-invasive, non-radiating technique, offers the following advantages, beyond echo:

a) more reliable and reproducible measurements of cardiac parameters such as volumes, ejection fraction and cardiac mass b) more accurate differentiation of LVH etiology by providing information about tissue characterisation c) more accurate evaluation of myocardial ischemia, specifically if small vessels disease is present d) technique of choice for diagnosis of renovascular, aortic tree/branches lesions and quantification of aortic valve regurgitation e) technique of choice for treatment evaluation in clinical trials.

The superiority of CMR against echocardiography in terms of reproducibility, operator independency, unrestricted field of view and capability of tissue characterization makes the technique ideal for evaluation of heart, quantification of aortic valve regurgitation, aorta and aortic branches.

Conclusions

CMR has a great potential in early diagnosis, risk stratification and treatment follow up of HHD. However, an international consensus about CMR in HHD, taking under consideration the cost-benefit ratio, expertise and availability, is still warranted.

Peer Review reports

Background

Alterations occurring in hypertensive heart disease (HHD) and the role of non-invasive cardiac imaging

Arterial hypertension is the commonest cause of cardiovascular death. It may lead to hypertensive heart disease (HHD) including heart failure (HF), ischemic heart disease (IHD) and left ventricular hypertrophy (LVH). There is no consensus among new HTN practice guidelines as to target treatment of blood pressure (BP) among various subpopulations of patients. However, most guidelines now target a BP < 150/90 for patients >80y, a BP < 140/90 for patients with diabetes or CVD and a BP < 130/80 if diabetes, albuminuria, or high stroke risk is present. In United States, 1 out of every 3 adults has high BP. About 69% of people with first heart attack, 77% with first stroke and 74% with HF have BP higher than 140/90 mmHg [1].

Essential hypertension accounts for 90% of adult cases and secondary causes of hypertension for the remaining 10%. According to the Framingham Study, hypertension accounts for about 1/4 of HF cases, and the risk of HF is increased by 2-fold in men, and 3-fold in women, respectively. Finally, hypertension affects other target organs including kidneys, eyes and peripheral arteries [2].

Left ventricular hypertrophy (LVH) is the response of myocytes to various stimuli leading to myocytes’ hypertrophy, which occurs as a compensatory response to increased afterload [2]. It is defined as an increase in LV mass, assessed by postmortem measurements, electrocardiographic (ECG), echocardiographic and Cardiovascular Magnetic Resonance (CMR) criteria. Early echocardiographic studies defined LVH as an absolute LV mass (LVM) exceeding 250 g [2]. Regression of LVH with antihypertensive treatment reduces the risk of stroke, myocardial infarction and all-cause mortality [2]. There are two main patterns of LVH: a) concentric and b) eccentric LVH [2]. Concentric LVH is considered, when LV mass increases by wall thickening in response to pressure overload, as often in middle aged and elderly patients, is associated with lower cardiac output and predicts poor prognosis. There is a pathway from hypertension to concentric LVH without focal scar [3], hypertension to concentric LVH with focal scar [4], concentric remodelling with myocardial infarction assessed by replacement fibrosis [5], and concentric LVH with symptomatic vascular events and heart failure either with replacement scar [6] or without [7, 8]. Diastolic dysfunction and/or heart failure with preserved ejection fraction (HFpEF), due to remodelling of the extracellular matrix and increase in LV filling pressures, are common in concentric LVH [9,10,11,12,13,14]. In eccentric LVH, there is an increase in LV mass without increased concentricity and is associated with higher cardiac output [8] (Fig. 2). It has not been fully clarified why patients develop a specific LVH pattern, as a response to hypertension. Factors such as pressure, volume overload, ethnicity, gender, obesity and plasma renin levels, all seems to play a role [2]; however, the clinical implications of various LVH patterns are still under evaluation. The aim of this review is to discuss the potential advantages and disadvantages of CMR over the currently used echocardiographic techniques and clarify its additive value in the evaluation of HHD.

“Needs and wants” in HHD evaluation

Various non-invasive techniques have been used to elucidate the pattern of HHD, including HFpEF. ECG and echocardiography were for many years the only techniques for evaluation of HHD. Although ECG measures of LVH were associated with cardiovascular disease risk in the Framingham study [15], the ECG evaluation of LVH lacks sensitivity and specificity, particularly in young male patients [16, 17].

Recently, a discrepancy documented in diagnostic performance and agreement on predictive ability suggests that LVH by ECG and LVH by CMR are likely to be two distinct phenotypes [18].

Echocardiography has been successfully used in clinical trials and provided important knowledge in HHD [19]. LVM assessment is useful in severe LVH; however, due to high variability, it underscores patients with mild concentric, eccentric LVH and/or concentric remodelling. Additionally, a large patients’ sample is required to document LVM regression, using M-mode or 2D echocardiography, due to high inter-observer and inter-study variability [20].

CMR, due to its excellent reproducibility, unrestricted field of view and non-invasive, non-radiating tissue characterization, became a powerful player for early diagnosis and treatment assessment of HHD and gender-specific values according to age and body surface area have been already published [21]. The comparison between new echocardiographic techniques and CMR showed that the assessment of LV volumes/LVEF by echocardiography and CMR have good correlations. However, the inter-technique agreement of absolute LV volumes revealed considerable differences, with significant underestimation of volumes and LVEF with respect to CMR [22]. Another study evaluating if LVM by real-time, 3-dimensional echocardiography (RT-3DE) corresponded to CMR in patients with LVH, showed that LVM by RT-3DE correlated with that determined by CMR better than that determined by 2DE, which means that RT-3DE can overcome some of the disadvantages of 2DE in the evaluation of LVM [23]. However, another study, evaluating the accuracy of LVM calculation using new echocardiographic techniques in comparison with CMR in ischemic (IC) and nonischemic cardiomyopathy (non-IC), documented that although more accurate and reliable echocardiographic measurement of LVM was achieved by 3DE, underestimation and variability remained challenges in IC [24]. Finally, a recent study, evaluating 40 patients by echocardiography using 4 imaging modalities (M-mode fundamental imaging [FI], M-mode harmonic imaging [HI], two-dimensional [2D] FI and 2D HI) and CMR, showed that HI overestimates LVM, compared with FI and CMR leading to overestimation of prevalence of LVH in hypertensive patients. HI improves inter-observer reproducibility of LVM measurements, compared with FI, leading to a significant decrease in the number of patients required for clinical trials of LVM regression. Finally, the accuracy of LVM measurements by echocardiography is affected by LV geometry [25, 26].

Speckle tracking (ST) alone or combined with tissue Doppler imaging (TDI) seems to be suitable for measurements of regional myocardial deformation and shows better agreement with CMR tagging for regional myocardial strain than measurements based solely on TDI; however, the clinical significance of the detected differences between the methods needs to be further established [27].

CMR “pearls and pitfalls” in the evaluation of HHD

According to the 2007 ESH/ESC guidelines the recommended imaging technique is echocardiography, when a more sensitive detection of LVH than that provided by ECG is needed, particularly in patients in whom organ damage is not detected by ECG, and in the elderly, in whom cardiac hypertrophy is frequent [28]. Additionally, in the 2010 ACCF/ACR/AHA/NASCI/SCMR Expert Consensus Document no recommendation about the usefulness of other techniques, including CMR in the assessment HHD, was discussed [29].

CMR provides a comprehensive non-invasive, non-radiating evaluation of HHD, including accurate and reproducible assessment of biventricular function, valvular disease, inflammation and stress myocardial perfusion-fibrosis. Its extensive application has the potential to lead to better understanding of pathophysiology of HHD, promoting more accurate risk stratification and personalised treatment. However, the extensive application of CMR is hampered by serious limitations, such as long examination time, lack of availability and expertise, time consuming post-processing and high cost. As any diagnostic technique, CMR carries various limitations. Scanning patients with metallic clips, pacemakers and other non CMR conditional cardiac devices is not indicated, due to safety reasons. Furthermore, paramagnetic contrast agents can not be used in patients with reduced glomerular filtration rate (GFR) < 30 mL/min/1.73 m2, due to risk of nephrogenic systemic fibrosis (NSF) [30], a scleroderma-like disease affecting the skin and internal organs [31]. If GFR is normal, its incidence is less than 1% [32]; however, in cases with reduced GFR, gadolinium should be given, only if: a) the expected benefits counterbalance the risks, b) using the lowest possible dose and c) avoiding the repeated use.

CMR sequences needed for evaluation of HHD

Specific sequences for cardiac evaluation include steady state free precession (SSFP) cines for function and wall motion assessment, phase contrast sequences for velocity evaluation, T2-weighted short-tau inversion recovery (STIR) for oedema assessment, T1- and T2-weighted fast spin-echo for tissue characterisation, T1- weighted perfusion and myocardial late gadolinium enhancement (LGE) sequences and 3D–magnetic resonance angiography (MRA). Other more sophisticated CMR techniques such as myocardial tagging, T1, T2 mapping are at the moment part of research in HHD. Currently, 3D–gadolinium enhanced MR angiography (MRA) is considered the imaging technique of choice for evaluation of renovascular hypertension and MRI is also excellent to localize tumours leading to pheochromocytoma and primary aldosteronism. However, at the moment, no specific indications for CMR in HHD have been proposed [33].

Comparison with other imaging techniques

The main imaging technique for comparison with CMR remains echocardiography, since both computed tomography (CT) and nuclear techniques are not included in the routine evaluation of HHD and are used only if there are specific indications. Compared with these techniques CMR has the following advantages:

High reproducibility of measurements

CMR is more reproducible than both M mode and 2D echocardiography for the estimation of LVM, because it does not require geometric assumptions, according to data validated by animal studies [24,25,26,27,28,29,30,31,32,33,34,35,36]. It provides an excellent contrast between blood and myocardium and has high spatial resolution, leading to accurate definition of endocardial and epicardial contours. Steady-state free precession (SSFP) cine imaging is the sequence of choice for measuring LVM by CMR. Usually, the absolute values of LVM by CMR are lower compared with echocardiography, because a) SSFP allows the visualization and inclusion of myocardial trabeculations in the LV volume with simultaneous exclusion from mass calculation b) the echocardiographic evaluation is based on geometric assumptions that is not the case for CMR

Easier and faster evaluation of treatment

CMR or 3D echocardiography are the techniques of choice in trials evaluating LVM regression, because they allow the accurate detection of small changes of LVM in small patients’ cohorts, particularly when recruitment of large patients’ numbers is not feasible. CMR, due to its high reproducibility, can demonstrate reduction in LVM and volumes with normalization of LVEF after a short period of better blood pressure (BP) control using appropriate medication [37, 38] and has been used to assess LVM regression after treatment of HHD in various studies including:

  1. a)

    the LIFE substudy in which the effect of high BP to ventricular remodelling was assessed [39]

  2. b)

    the TELMAR study [40], which compared the effect of telmisartan to metoprolol on LVH in uncontrolled hypertension

  3. c)

    the LVH-4E [41], in which eplerenone was compared to enalapril or a combination of both in LVH regression in hypertensive patients

  4. d)

    the ALIVE study [39], in which benazepril with either amlodipine or a diuretic was evaluated and recently

  5. e)

    the ALLAY trial [42], in which aliskiren, a direct renin inhibitor, was proved to be as effective as losartan for reduction of LVM.

Evaluation of intramyocardial function

CMR tissue tagging allowed the non-invasive assessment of intramyocardial displacement / strain by monitoring motion of specific material points spread in the myocardium [43,44,45,46,47]. The application of this technique in large epidemiologic studies such as the Multi-Ethnic Study of Atherosclerosis (MESA) [48] has enabled to investigate the nature of atherosclerosis in a total of 1184 asymptomatic participants (aged 45–84 years). Regional LV function was quantified by evaluating peak systolic circumferential strain (Ecc). The study proved that higher diastolic blood pressure (DBP) was associated with decreased regional LV function in asymptomatic individuals [49] and was significantly attenuated after controlling for LVM. Furthermore, LV torsional deformation was greater in hypertensive patients, despite that they had lower circumferential shortening, because torsion in hypertension with concentric remodeling is a compensatory mechanism to maintain LVEF [49].

In contrast, the echocardiographic evaluation of LV deformation is a geometry-based index, derived from linear measurements of the posterior and the septal wall and cannot distinguish between septal and posterior wall function. Thus, it is unknown, whether depressed LV deformation represents global or regional intrinsic depression of LV myocardial function in hypertrophy, due to pressure-overload [50]. In addition, the assessment of torsional deformation by echocardiography is methodologically challenging, because the distance between the basal and the apical short-axis slices can not be accurately assessed by this technique [50].

Diastolic dysfunction

Diastolic dysfunction is the earliest expression of HHD [51, 52], affects approximately 50% of hypertensive patients worldwide [52], correlates with the degree of LVH [53, 54] and is remarkably improved in cases with LVH regression (54). Currently, the most widely applied technique to assess LV diastolic function is the evaluation of transmitral inflow or pulmonary venous flows using Doppler echocardiography [55,56,57,58]. However, echocardiography measures the impact of altered LV diastolic properties by evaluating diastolic flow velocities, due to pressure gradient changes at the mitral orifice and flow velocities in the pulmonary veins and is unable to evaluate LV relaxation directly. Furthermore, the conventional Doppler measurements are very much load-dependent and can change dramatically during minimal alterations in heart rate and/or ventricular preload [58]. This defect can be overcome by the application of Tissue Doppler Imaging (TDI), which measures early diastolic mitral annular velocity (Ea) and late, due to atrial contraction, diastolic mitral annular velocity (Am) [59]. Ea of the lateral basal part of LV does not change significantly and any consequence, due to preload change, can be corrected by a ratio of E/Ea [59]. Additionally, 2D–speckle imaging provides a direct angle- and geometry-independent measure of circumferential strain (ε) [60, 61].

There is an excellent agreement between CMR and transthoracic echocardio-graphy for the assessment of diastolic inflow [62]. CMR has the potential to evaluate the diastolic function during both active and passive stages with the additive value of assessment of myocardial velocities [63], providing insights unavailable by other non-invasive imaging techniques. Recently, a novel CMR-derived index -diastolic volume recovery, calculated as the percentage proportion of diastole required for recovery of 80% stroke volume, has been shown to give the best result, compared with echocardiography for the detection of diastolic dysfunction [64]. Additionally, atrial size is an independent factor associated with CV morbidity and mortality [65] and the possibility of atrial fibrillation [66]. Assessment of atrial volumes by echocardio-graphy is inaccurate, due to geometric assumptions about their shape [67]. In contrary, CMR offers an accurate and reproducible measurement of atrial volumes and recently reference values of left atrial volume by CMR became available [68]. However, until now, due to high availability and temporal resolution of echocardiography, CMR has not been used as a routine tool for diastolic function evaluation.

Differentiation of various causes of LVH

The differentiation of aetiology of LVH is intriguing, because various forms of LVH may present with overlapping phenotypes. Various myocardial abnormalities including infiltrative diseases, hypertrophic cardiomyopathy (HCM), Fabry’s disease, cardiac sarcoidosis, aortic stenosis and athlete’s heart can be presented with LVH.

CMR is superior to echocardiography for HCM diagnosis, by identifying areas of segmental hypertrophy (ie, anterolateral wall or apex) not reliably visualized by echocardiography (or underestimated in extent). High-risk HCM subgroups, identified with CMR, include those with thin-walled scarred LV apical aneurysms (which prior to CMR imaging remained usually undetected), end-stage systolic dysfunction and massive LV hypertrophy. CMR observations also suggest that the cardiomyopathic process in HCM is more diffuse than previously observed, extending beyond the LV myocardium to include thickening of the right ventricular wall as well as substantial morphologic diversity with regard to papillary muscles and mitral valve. These findings have implications for management in HCM undergoing invasive septal reduction therapy. Among HCM families, CMR has identified unique phenotypes of affected genetic status in the absence of LV hypertrophy, including myocardial crypts, elongated mitral valve leaflets and late gadolinium enhancement [69]. CMR may also raise suspicion of various infiltrative cardiomyopathies, such as cardiac amyloidosis, glyocogen/lysosomal storage diseases including Fabry’s, Danons, and AMP kinase diseases. The demonstration of nearly identically increased wall thickness in both the septum and LV free wall, by cine CMR, combined with diffuse subendocardial LGE is highly specific for cardiac amyloidosis. A similar pattern of concentric wall thickening with LGE confined to the basal inferolateral wall has been frequently reported in Fabry’s disease. CMR may suggest the aetiology of LVH; however, confirmatory diagnosis requires the identification of a disease-causing mutation by genetic testing or typical histopathology on cardiac biopsy [69].

CMR can be also helpful in detecting changes in serial measurements of LV wall thickness after treatment with antihypertensives, in which regression of hypertrophy supports the diagnosis of hypertensive cardiomyopathy. In hypertensive patients, CMR documented reduced ejection fraction/anteroseptal systolic strains and increased cardiac chamber volumes/LV wall stress, while in HCM, revealed supernormal ejection fraction, reduced LV wall stress/longitudinal systolic strain and fibrosis. Increased LV wall stress was the hallmark of hypertension, while HCM was characterized by reduced total longitudinal strain. Finally, athlete’s heart was distinguished from other types of hypertrophy by using the CMR-derived diastolic wall-to-volume ratio [70]. Although it needs further validation, a cut-off value of less than 0.15 mm × m2/ml has 99% specificity for sport-related LVH [70].

To conclude, although ECG has high specificity for the detection of LVH, it is unable to identify the type of hypertrophy. This is because the ECG thresholds are generally selected to optimize specificity. Finally, standard ECG criteria for LVH have low sensitivity for CMR LVH, and few false positives and more false negatives.Echocardiography, although widely available and cost effective, carries the significant disadvantages of operator and acoustic window dependency and restricted field of view. In contrary, the CMR capability to offer detailed and highly reproducible wall motion evaluation without assumptions and concurrent tissue characterisation can significantly facilitate the differential diagnosis of various diseases presented with LVH.

Fibrosis assessment

Myocardial fibrosis is the common end point of various pathologic processes in HHD and plays an important role in the development of diastolic dysfunction [71, 72]. The most robust approach to quantify replacement myocardial fibrosis is late gadolinium enhancement (LGE) [73]; it represents gadolinium enhancement in regions of fibrosis using T1-weighted images, taken 10–15 min after intravenous administration of gadolinium-based contrast agent. The pathophysiologic mechanism behind LGE includes a) expansion of extravascular volume in fibrotic myocardium, occupied by the extracellular distribution of contrast agent b) impaired kinetics of gadolinium due to vascular changes in fibrotic myocardium. Patchy LGE has been documented in approximately 50% of patients with LVH due to arterial hypertension [74], and was clearly distinguishable from the subendocardial LGE (Fig. 4), due to myocardial infarction. LGE can be also found in hypertrophic cardiomyopathy, and its quantification can differentiate those patients in high risk for sudden cardiac death [75] (Figs. 1, 2, 3 and 4).

Fig. 1
figure1

Four chamber LGE in a patient with extensive hypertrophy due to HCM. There are clear fibrotic areas in the interventricular septum, lateral wall of LV and apex, providing diagnostic and prognostic information about future cardiac events

Full size image
Fig. 2
figure2

Short axis LGE in a patient with with amyloidosis. Evidence of amyloid depositions in both ventricles (arrows)

Full size image
Fig. 3
figure3

Short axis LGE in a patient with HHD and evidence of intranyocardial fibrosis in the interventricular septum

Full size image
Fig. 4
figure4

Subendocardial LGE in the lateral wall of LV, due to myocardial infarction in a patient with coronary artery disease

Full size image

Recent studies proved that the severity of diastolic dysfunction increases in parallel with the extent of fibrosis, assessed by LGE [76]. However, discrete LGE areas may be absent in HHD. Unfortunately, diffuse myocardial fibrosis can not be detected by LGE, because LGE relies on the signal intensity differences between fibrotic and normal myocardium and this is a serious drawback of the technique. This phenomenon has motivated the development of the technique of T1 mapping by which quantification of diffuse myocardial fibrosis can be achieved; T1 mapping represents an independent discriminator between HCM and hypertension, over and above extracellular volume fraction (ECV), LV wall thickness and indexed LVM [77]. There are data demonstrating significant differences in myocardial contrast accumulation between controls and HF patients using post-contrast T1 mapping with concurrent histologic data supporting that these changes reflect diffuse fibrosis. T1 mapping has the potential to be the end point in future trials, assessing antifibrotic treatment in HHD, without using serial endomyocardial tissue biopsies [4, 78, 79].

Finally, in well-controlled hypertensive patients, conventional CMR discovered significant underlying diseases (infarction, HCM), undetected by echocardiography. In these patients, T1 mapping revealed increased diffuse myocardial fibrosis, but this increase was small and only occurred with LVH [80]. However, in another study T1 mapping was an independent discriminator between HCM and hypertension, over and above extracellular volume fraction (ECV), LV wall thickness and LVM [81].

Although tissue biopsy is the gold standard for diagnosis of myocardial fibrosis, some circulating biomarkers have been also proposed for the non-invasive assessment of fibrosis. It was suggested that galectin-3 (Gal-3) is associated with myocardial histological and molecular parameters related to fibrosis and with the circulating biomarkers of the extracellular generation of mature fibril-forming collagen types I (C-terminal propeptide of procollagen type I, PICP) and III (N-terminal propeptide of procollagen type III, PIIINP) in two independent studies of hypertensive patients with heart failure (HF). However, data from various studies are rather contradictory. The excess of cardiac and systemic Gal-3 in HF patients of hypertensive origin was not associated with histological, molecular and/or biochemical parameters related to myocardial fibrosis in these patients [82]. Furthermore, a review of the literature about biomarkers showed that most of them lack proof for representing true myocardial fibrosis [83]. However, in another study, elevated serum levels of Gal-3 were in agreement with the degree of myocardial fibrosis assessed by LGE [84].

Ischemia detection

In HHD, coronary circulation changes take place, independently of occlusive atherosclerotic disease of epicardial coronary arteries. Furthermore, abnormalities in the coronary microcirculation, which accompany cardiac hypertrophy, play an important role in the pathophysiology of complications, attributed to LVH [85]. Although in clinical practice, the ECG is the first test to assess LVH [86, 87], false positives results are very common. Furthermore, a normal ECG can not exclude LVH [88]. Myocardial perfusion scintigraphy can potentially have a place in the detection of reduced coronary flow reserve in HHD. However, there are several technical issues with this technique in HHD, because any myocardial pathology, frequently assessed in these patients, can lead to abnormal images. Patients with HHD and concurrent LVH may have perfusion defects, unrelated to coronary artery disease (CAD). Their images can be false interpreted as evidence of myocardial ischemia, due to CAD [89, 90]. Furthermore, in HHD with LVH and/or microvascular disease, myocardial perfusion abnormalities were frequently documented in hypertensive patients with associated angiographically normal epicardial coronary arteries [90]. Stress echocardiography has a better specificity for detection of angiographically documented CAD [91]; however, the sensitivity of wall motion abnormalities for ischemia detection was significantly reduced, when LVH coexisted.

Stress perfusion CMR permits the non-invasive differentiation between hemodynamically significant coronary artery stenosis and microvascular disease, due to hypertension and/or diabetes, based on high temporal and spatial resolution of the technique. In small vessel disease, the perfusion defects are usually diffuse, circumferential, affecting ≤1/3 of the wall thickness and have shorter persistence (≤ 5 heartbeats) compared with those in patients with significant epicardial coronary disease (Fig. 5) [92,93,94,95]. This differentiation is important for both treatment and prognosis [96, 97]. CMR can also identify coronary flow abnormalities in HHD with normal coronary arteries [98, 99]. Additionally, more than half of the scar detected by CMR-LGE was undetected by ECG [5, 6].

Fig. 5
figure5

Diffuse subendocardial perfusion defect, detected by adenosine stress perfusion CMR, in a patient with HHD

Full size image

CMR indications in HHD

Clinical evaluation, ECG and echocardiography constitute the cornerstones for both diagnosis and follow up of HHD and remain the absolutely necessary examinations for HHD patients. However, a CMR evaluation is indicated if there is a) an inconclusive echocardiogram, b) a mismatch between clinical evaluation, ECG and echocardiography and c) severe, rapidly progressive LVH. Finally, due to high reproducibility, it is the ideal tool for clinical trials. In more details, the CMR indications in HHD are presented in Table 1.

Table 1 Potential CMR indications in hypertensive heart disease
Full size table

Conclusions

HHD is the commonest cause of cardiovascular death with detrimental impact on patients’ morbidity and mortality and also health care costs. Although detailed guidelines determining the clinical indications of CMR in hypertension are still missing, CMR can provide early and highly reproducible evaluation of LVH and remodelling, not available by any other non-invasive technique; furthermore, the capability to perform tissue characterisation facilitates the early diagnosis and better risk stratification of micro-, macro-vascular ischemia and fibrosis, commonly found in hypertensive patients, with potentially high impact on their treatment and also on health care costs.

Key points

  1. 1.

    Hypertensive heart disease (HHD) includes

    a) Left ventricular hypertrophy (LVH),

    b) congestive heart failure (CHF),

    c) ischemic heart disease (IHD)

  2. 2.

    ECG evaluation of LVH lacks sensitivity and specificity, particularly in young male patients

  3. 3.

    2D Echocardiographic assessment of LV mass (LVM) is useful in patients with severe LVH; however, it has high interobserver/interstudy variability

  4. 4.

    LV mass assessed by RT-3DE correlates with CMR better than that determined by 2DE; however, underestimation and variability remain challenges in patients with ischemic cardiomyopathy

  5. 5.

    CMR offers:

    a) High reproducibility of measurements

    b) Easier and faster evaluation of treatment

    c) Evaluation of intramyocardial function

    d) Evaluation of Diastolic dysfunction

    e) Differentiation of various causes of LVH

    f) Fibrosis assessment

    g) Ischemia detection

Abbreviations

2D E:

2 Dimentional Echocardiography

Am:

Atrial contraction, diastolic mitral annular velocity

CAD:

Coronary artery disease

CHF:

Congestive heart failure

CMR:

Cardiovascular Magnetic Resonance

Ea:

Early diastolic mitral annular velocity

ECG:

Electrocardiogram

EF:

Ejection fraction

FI:

M-mode fundamental imaging

Gal-3:

Galectin 3

HCM:

Hypertrophic Cardiomyopathy

HF:

Heart failure

HFpEF:

Heart failure with preserved ejection fraction

HHD:

Hypertensive heart disease

HI:

M-mode harmonic imaging

IHD:

Ischemic heart disease

IHD:

Ischemic heart disease

IVS:

Intra-ventricular septal

LGE:

Late gadolinium enhancement

LV:

Left ventricle

LVH:

Left ventricular hypertrophy

LVM:

Left ventricular mass

NSF:

Nephrogenic fibrosis syndrome

PICP:

C-terminal propeptide of procollagen type I

PIIINP:

N-terminal propeptide of procollagen type III

RT-3DE:

3 Dimentional Echocardiography

RV:

Right ventricle

SSFP:

Steady-state free precession

STIR:

T2 T2-weighted short-tau inversion recovery

References

  1. 1.

    Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, DK MG, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB, on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013;127:e6–e245.

    Article  PubMed  Google Scholar 

  2. 2.

    Drazner MH. The progression of hypertensive heart disease. Circulation. 2011;123(3):327–34.

    Article  PubMed  Google Scholar 

  3. 3.

    Yoneyama K, Gjesdal O, Choi EY, et al. Age, sex, and hypertension-related remodeling influences left ventricular torsion assessed by tagged cardiac magnetic resonance in asymptomatic individuals: the multi-ethnic study of atherosclerosis. Circulation. 2012;126:2481–90.

    Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Ambale Venkatesh B, Volpe GJ, Donekal S, et al. Association of longitudinal changes in left ventricular structure and function with myocardial fibrosis: the multi-ethnic study of atherosclerosis study. Hypertension. 2014;64:508–15.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Turkbey EB, Nacif MS, Guo M, et al. Prevalence and correlates of myocardial scar in a US cohort. JAMA. 2015;314:1945–54.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Schelbert EB, Cao JJ, Sigurdsson S, et al. Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults. JAMA. 2012;308:890–6.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Bluemke DA, Kronmal RA, Lima JA, et al. The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (multi-ethnic study of atherosclerosis) study. J Am Coll Cardiol. 2008;52:2148–55.

    Article  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Chahal H, Bluemke DA, Wu CO, et al. Heart failure risk prediction in the multi-ethnic study of atherosclerosis. Heart. 2015;101:58–64.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med. 1990;322(22):1561–6.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Berk BC, Fujiwara K, Lehoux S. ECM remodelling in hypertensive heart disease. J Clin Invest. 2007;117(3):568–75.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Liu CY, Liu YC, Wu C, et al. Evaluation of age-related interstitial myocardial fibrosis with cardiac magnetic resonance contrast-enhanced T1 mapping: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol. 2013;62:1280–7.

    Article  PubMed  Google Scholar 

  12. 12.

    Houghton JL, Frank MJ, Carr AA, von Dohlen TW, Prisant LM. Relations among impaired coronary flow reserve, left ventricular hypertrophy and thallium perfusion defects in hypertensive patients without obstructive coronary artery disease. J Am Coll Cardiol. 1990;15:43–51.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Davies JE, Whinnett ZI, Francis DP, et al. Evidence of a dominant backward-propagating “suction” wave responsible for diastolic coronary filling in humans, attenuated in left ventricular hypertrophy. Circulation. 2006;113:1768–78.

    Article  PubMed  Google Scholar 

  14. 14.

    Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55(4):613–8.

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. Ann Intern Med. 1969;71(1):89–105.

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Pewsner D, Jüni P, Egger M, Battaglia M, Sundström J, Bachmann LM. Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. BMJ. 2007;335(7622):711.

    Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Bratincsák A, Williams M, Kimata C, Perry JC. The electrocardiogram is a poor diagnostic tool to detect left ventricular hypertrophy in children: a comparison with Echocardiographic assessment of left ventricular Mass Congenit Heart Dis 2015; 10(4):E164-E171.

  18. 18.

    Bacharova L, Chen H, Estes EH, Mateasik A, Bluemke DA, Lima JA, Burke GL, Soliman EZ. Determinants of discrepancies in detection and comparison of the prognostic significance of left ventricular hypertrophy by electrocardiogram and cardiac magnetic resonance imaging. Am J Cardiol. 2015;115(4):515–22.

    Article  PubMed  Google Scholar 

  19. 19.

    Devereux RB, Dahlof B, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint reduction in Hypertension (LIFE) trial. Circulation. 2004;110:1456–62.

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Grothues F, Smith GC, Moon JC, et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol. 2002;90(1):29–34.

    Article  PubMed  Google Scholar 

  21. 21.

    Alfakih K, Walters K, Jones T, Ridgway J, Hall AS, Sivananthan M. New gender-specific partition values for ECG criteria of left ventricular hypertrophy: recalibration against cardiac MRI. Hypertension. 2004;44(2):175–9.

    CAS  Article  PubMed  Google Scholar 

  22. 22.

    Aurich M, André F, Keller M, Greiner S, Hess A, Buss SJ, Katus HA, Mereles D. Assessment of left ventricular volumes with echocardiography and cardiac magnetic resonance imaging: real-life evaluation of standard versus new semiautomatic methods. J Am Soc Echocardiogr. 2014;27(10):1017–24.

    Article  PubMed  Google Scholar 

  23. 23.

    Oe H, Hozumi T, Arai K, Matsumura Y, Negishi K, Sugioka K, Ujino K, Takemoto Y, Inoue Y, Yoshikawa J. Comparison of accurate measurement of left ventricular mass in patients with hypertrophied hearts by real-time three-dimensional echocardio-graphy versus magnetic resonance imaging Am J Cardiol. 2005;95(10):1263–7.

    Article  PubMed  Google Scholar 

  24. 24.

    Kusunose K, Kwon DH, Motoki H, Flamm SD, Marwick TH. Comparison of three-dimensional echocardiographic findings to those of magnetic resonance imaging for determination of left ventricular mass in patients with ischemic and non-ischemic cardiomyopathy. Am J Cardiol. 2013;112(4):604–11.

    Article  PubMed  Google Scholar 

  25. 25.

    Perdrix L, Mansencal N, Cocheteux B, Chatellier G, Bissery A, Diebold B, Mousseaux E, Abergel E. How to calculate left ventricular mass in routine practice? An echocardiographic versus cardiac magnetic resonance study. Arch Cardiovasc Dis. 2011;104(5):343–51.

    Article  PubMed  Google Scholar 

  26. 26.

    Park JH, Negishi K, Kwon DH, Popovic ZB, Grimm RA, Marwick TH. Validation of global longitudinal strain and strain rate as reliable markers of right ventricular dysfunction: comparison with cardiac magnetic resonance and outcome. J Cardiovasc Ultrasound. 2014;22(3):113–20.

    Article  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Amundsen BH, Crosby J, Steen PA, Torp H, Slørdahl SA, Støylen A. Regional myocardial long-axis strain and strain rate measured by different tissue Doppler and speckle tracking echocardiography methods: a comparison with tagged magnetic resonance imaging. Eur J Echocardiogr. 2009;10(2):229–37.

    PubMed  Google Scholar 

  28. 28.

    The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Guidelines for the management of arterial Hypertensión. Eur Heart J. 2007;28:1462–536.

    Google Scholar 

  29. 29.

    American College of Cardiology Foundation Task Force on Expert Consensus Documents, Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG, Ho VB, Jerosch-Herold M, Kramer CM, Manning WJ, Patel M, Pohost GM, Stillman AE, White RD, Woodard PK. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on expert consensus documents. J Am Coll Cardiol. 2010;55:2614–62.

    Article  Google Scholar 

  30. 30.

    Varghese A, Crowe LA, Mohiaddin RH, Gatehouse PD, Yang GZ, Firmin DN, et al. Inter-study reproducibility of 3D volume selective fast spin echo sequence for quantifying carotid artery wall volume in asymptomatic subjects. Atherosclerosis. 2005;183:361–6.

    CAS  Article  PubMed  Google Scholar 

  31. 31.

    Sadowski EA, Bennett LK, Chan MR, Wentland AL, Al G, Garrett RW, Djamali A. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243:148–57.

    Article  PubMed  Google Scholar 

  32. 32.

    Reiter T, Ritter O, Prince MR, Nordbeck P, Wanner C, Nagel E, Bauer WR. Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012;14:31.

    Article  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Maceira and Mohiaddin. Cardiovascular magnetic resonance in systemic hypertension J Cardiovasc Magn Reson 2012; 14:28.

  34. 34.

    Katz J, Milliken MC, Stray-Gundersen J, et al. Estimation of human myocardial mass with MR imaging. Radiology. 1988;169(2):495–8.

    CAS  Article  PubMed  Google Scholar 

  35. 35.

    Florentine MS, Grosskreutz CL, Chang W, et al. Measurement of left ventricular mass in vivo using gated nuclear magnetic resonance imaging. J Am Coll Cardiol. 1986;8(1):107–12.

    CAS  Article  PubMed  Google Scholar 

  36. 36.

    Keller AM, Peshock RM, Malloy CR, et al. In vivo measurement of myocardial mass using nuclear magnetic resonance imaging. J Am Coll Cardiol. 1986;8(1):113–7.

    CAS  Article  PubMed  Google Scholar 

  37. 37.

    Reichek N, Devereux RB, Rocha RA, et al. Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension. Hypertension. 2009;54(4):731–7.

    CAS  Article  PubMed  Google Scholar 

  38. 38.

    Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108(15):1831–8.

    CAS  Article  PubMed  Google Scholar 

  39. 39.

    Olsen MH, Wachtell K, Hermann KL, Frandsen E, Dige-Petersen H, Rokkedal J, Devereux R, Ibsen H. Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention for Endpoint-reduction in Hypertension. Am Heart J. 2002;144:530–7.

    Article  PubMed  Google Scholar 

  40. 40.

    Friedrich MG, Dahlof B, Sechtem U, Unger T, Knecht M, Dietz R. TELMAR investigators. Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension–a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of 6 months rationale and study design. J Renin-Angiotensin-Aldosterone Syst. 2003;4:234–43.

    CAS  Article  PubMed  Google Scholar 

  41. 41.

    Williams GH, Burgess E, Kolloch RE, Ruilope LM, Niegowska J, Kipnes MS, Roniker B, Patrick JL, Krause SL. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol. 2004 Apr 15;93(8):990–6.

    CAS  Article  PubMed  Google Scholar 

  42. 42.

    Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif Papst C, Smith BA, Dahlöf B. Aliskiren in left ventricular hypertrophy (ALLAY) trial investigators. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009;119:530–7.

    CAS  Article  PubMed  Google Scholar 

  43. 43.

    Axel L, Dougherty L. MR imaging of motion with spatial modulation of magnetization. Radiology. 1989;171(3):841–5.

    CAS  Article  PubMed  Google Scholar 

  44. 44.

    Young AA, Imai H, Chang CN, Axel L. Two-dimensional left ventricular deformation during systole using magnetic resonance imaging with spatial modulation of magnetization. Circulation. 1994;89(2):740–52.

    CAS  Article  PubMed  Google Scholar 

  45. 45.

    Clark NR, Reichek N, Bergey P, et al. Circumferential myocardial shortening in the normal human left ventricle. Assessment by magnetic resonance imaging using spatial modulation of magnetization. Circulation. 1991;84(1):67–74.

    CAS  Article  PubMed  Google Scholar 

  46. 46.

    Palmon LC, Reichek N, Yeon SB, et al. Intramural myocardial shortening in hypertensive left ventricular hypertrophy with normal pump function. Circulation. 1994;89(1):122–31.

    CAS  Article  PubMed  Google Scholar 

  47. 47.

    Osman NF, Prince JL. Visualizing myocardial function using HARP MRI. Phys Med Biol. 2000;45(6):1665–82.

    CAS  Article  PubMed  Google Scholar 

  48. 48.

    Rosen BD, Saad MF, Shea S, et al. Hypertension and smoking are associated with reduced regional left ventricular function in asymptomatic: individuals the multi-ethnic study of atherosclerosis. JAm Coll Cardiol. 2006;47(6):1150–8.

    Article  Google Scholar 

  49. 49.

    Gaasch WH, Zile MR. Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med. 2004;55:373–94.

    CAS  Article  PubMed  Google Scholar 

  50. 50.

    Tadic M, Cuspidi C, Majstorovic A, Kocijancic V, Celic V. The relationship between left ventricular deformation and different geometric patterns according to the updated classification: findings from the hypertensive population J Hypertens 2015; 33(9):1954-1961.

  51. 51.

    Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289(2):194–202.

    Article  PubMed  Google Scholar 

  52. 52.

    Wachtell K, Smith G, Gerdts E, et al. Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Losartan Intervention for Endpoint. Am. J. Cardiology. 2000;85(4):466–72.

    CAS  Google Scholar 

  53. 53.

    Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: part I: diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002;105(11):1387–93.

    Article  PubMed  Google Scholar 

  54. 54.

    Smith VE, White WB, Meeran MK, Karimeddini MK. Improved left ventricular filling accompanies reduced left ventricular mass during therapy of essential hypertension. J Am Coll Cardiol. 1986;8(6):1449–54.

    CAS  Article  PubMed  Google Scholar 

  55. 55.

    Nishimura RA, Tajik AJ. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta stone. J Am Coll Cardiol. 1997;30(1):8–18.

    CAS  Article  PubMed  Google Scholar 

  56. 56.

    Schillaci G, Pasqualini L, Verdecchia P, et al. Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol. 2002;39(12):2005–11.

    Article  PubMed  Google Scholar 

  57. 57.

    Ishida Y, Meisner JS, Tsujioka K, et al. Left ventricular filling dynamics: influence of left ventricular relaxation and left atrial pressure. Circulation. 1986;74(1):187–96.

    CAS  Article  PubMed  Google Scholar 

  58. 58.

    Choong CY, Herrmann HC, Weyman AE, Fifer MA. Preload dependence of Doppler-derived indexes of left ventricular diastolic function in humans. J Am Coll Cardiol. 1987;10(4):800–8.

    CAS  Article  PubMed  Google Scholar 

  59. 59.

    Waggoner AD, Bierig SM. Tissue Doppler imaging: a useful echocardiographic method for the cardiac sonographer to assess systolic and diastolic ventricular function. J Am Soc Echocardiogr. 2001;14(12):1143–52.

    CAS  Article  PubMed  Google Scholar 

  60. 60.

    Hurlburt HM, Aurigemma GP, Hill JC, et al. Direct ultrasound measurement of longitudinal, circumferential, and radial strain using 2-dimensional strain imaging in normal adults. Echocardiography. 2007;24(7):723–31.

    Article  PubMed  Google Scholar 

  61. 61.

    Narayanan A, Aurigemma GP, Chinali M, Hill JC, Meyer TE, Tighe DA. Cardiac mechanics in mild hypertensive heart disease: a speckle-strain imaging study. Circ Cardiovasc Imaging. 2009;2(5):382–90.

    Article  PubMed  Google Scholar 

  62. 62.

    Rathi VK, Doyle M, Yamrozik J, et al. Routine evaluation of left ventricular diastolic function by cardiovascular magnetic resonance: a practical approach. J Cardiovasc Magn Reson. 2008;10:36.

    Article  PubMed  PubMed Central  Google Scholar 

  63. 63.

    Rathi VK, Biederman RW. Expanding role of cardiovascular magnetic resonance in left and right ventricular diastolic function. Heart Fail Clin. 2009;5(3):421–35.

    Article  PubMed  Google Scholar 

  64. 64.

    Rossi A, Temporelli PL, Quintana M, Dini FL, Ghio S, Hillis GS, Klein AL, Marsan NA, Prior DL, Yu CM, Poppe KK, Doughty RN, Whalley GA. MeRGE heart failure collaborators. Independent relationship of left atrial size and mortality in patients with heart failure: an individual patient meta-analysis of longitudinal data (MeRGE heart failure). Eur J Heart Fail. 2009;11:929–36.

    Article  PubMed  Google Scholar 

  65. 65.

    Bangalore S, Yao SS, Chaudhry FA. Role of left atrial size in risk stratification and prognosis of patients undergoing stress echocardiography. J Am Coll Cardiol. 2007;50:1254–62.

    Article  PubMed  Google Scholar 

  66. 66.

    Therkelsen SK, Groenning BA, Svendsen JH, Jensen GB. Atrial and ventricular volume and function in persistent and permanent atrial fibrillation, a magnetic resonance imaging study. J Cardiovasc Magn Reson. 2005;7:465–73.

    Article  PubMed  Google Scholar 

  67. 67.

    Raman SV. The hypertensive heart. An integrated understanding informed by imaging. J. Am.Coll. Cardiology. 2010;55(2):91–6.

    Google Scholar 

  68. 68.

    Maceira AM, Cosín-Sales J, Roughton M, Prasad SK, Pennell DJ. Reference left atrial dimensions and volumes by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2010;12:65.

    Article  PubMed  PubMed Central  Google Scholar 

  69. 69.

    Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic Cardiomyopathy. J Cardiovasc Magn Reson. 2012;14(1):13.

    Article  PubMed  PubMed Central  Google Scholar 

  70. 70.

    Petersen SE, Selvanayagam JB, Francis JM, Myerson SG, Wiesmann F, Robson MD, Ostman-Smith I, Casadei B, Watkins H, Neubauer S. Differentiation of athlete’s heart from pathological forms of cardiac hypertrophy by means of geometric indices derived from cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2005;7:551–8.

    Article  PubMed  Google Scholar 

  71. 71.

    Rudolph A, Abdel-Aty H, Bohl S, et al. Noninvasive detection of fibrosis applying contrast enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodelling. J Am Coll Cardiol. 2009;53:284–91.

    Article  PubMed  Google Scholar 

  72. 72.

    Moreo A, Ambrosio G, De Chiara B, et al. Influence of myocardial fibrosis on left ventricular diastolic function: noninvasive assessment by cardiac magnetic resonance and echo. Circ Cardiovasc Imaging. 2009;2(6):437–43.

    Article  PubMed  PubMed Central  Google Scholar 

  73. 73.

    Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000;102:1388–93.

    CAS  Article  PubMed  Google Scholar 

  74. 74.

    Marcus ML, Koyanagi S, Harrison DG, Doty DB, Hiratzka LF, Eastham CL. Abnormalities in the coronary circulation that occur as a consequence of cardiac hypertrophy. Am J Med. 1983;75(3A):62–6.

    CAS  Article  PubMed  Google Scholar 

  75. 75.

    Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, Lesser JR, Gruner C, Crean AM, Rakowski H, Udelson JE, Rowin E, Lombardi M, Cecchi F, Tomberli B, Spirito P, Formisano F, Biagini E, Rapezzi C, De Cecco CN, Autore C, Cook EF, Hong SN, Gibson CM, Manning WJ, Appelbaum E, Maron MS. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130(6):484–95.

    Article  PubMed  Google Scholar 

  76. 76.

    Kawaji K, Codella NC, Prince MR, Chu CW, Shakoor A, LaBounty TM, Min JK, Swaminathan RV, Devereux RB, Wang Y, Weinsaft JW. Automated segmentation of routine clinical cardiac magnetic resonance imaging for assessment of left ventricular diastolic dysfunction. Circ Cardiovasc Imaging. 2009;2:476–84.

    Article  PubMed  Google Scholar 

  77. 77.

    Hinojar R, Varma N, Child N, Goodman B, Jabbour A, Yu CY, Gebker R, Doltra A, Kelle S, Khan S, Rogers T, Arroyo Ucar E, Cummins C, Carr-White G, Nagel E, Puntmann VO. T1 mapping in discrimination of hypertrophic phenotypes: hypertensive heart disease and hypertrophic Cardiomyopathy: findings from the international T1 multicenter cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2015:8(12).

  78. 78.

    López B, González A, Querejeta R, Zubillaga E, Larman M, Díez J. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. Eur J Heart Fail. 2015;17(4):385–92.

    Article  PubMed  Google Scholar 

  79. 79.

    Tandon A, Villa CR, Horn KN et al. J Am Heart Assoc. 2015;4(4).

  80. 80.

    Treibel TA, Zemrak F, Sado DM, Banypersad SM, White SK, Maestrini V, Barison A, Patel V, Herrey AS, Davies C, Caulfield MJ, Petersen SE, Moon JC. Extracellular volume quantification in isolated hypertension - changes at the detectable limits? J Cardiovasc Magn Reson. 2015;17:74.

    Article  PubMed  PubMed Central  Google Scholar 

  81. 81.

    Hinojar R, Varma N, Child N, Goodman B, Jabbour A, Yu CY, Gebker R, Doltra A, Kelle S, Khan S, Rogers T, Arroyo Ucar E, Cummins C, Carr-White G, Nagel E, Puntmann VO. T1 mapping in discrimination of hypertrophic phenotypes: hypertensive heart disease and hypertrophic Cardiomyopathy: findings from the international T1 multicenter cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2015;8(12):e003285.

    Article  PubMed  Google Scholar 

  82. 82.

    López B, González A, Ravassa S, Beaumont J, Moreno MU, San José G, Querejeta R, Díez J. Circulating biomarkers of myocardial fibrosis: the need for a reappraisal. J Am Coll Cardiol. 2015;65(22):2449–56.

    Article  PubMed  Google Scholar 

  83. 83.

    Lepojärvi ES, Piira OP, Pääkkö E, Lammentausta E, Risteli J, Miettinen JA, Perkiömäki JS, Huikuri HV, Junttila MJ. Serum PINP, PIIINP, galectin-3, and ST2 as surrogates of myocardial fibrosis and echocardiographic left venticular diastolic filling properties. Front Physiol. 2015;6:200.

    Article  PubMed  PubMed Central  Google Scholar 

  84. 84.

    Harvey A, Montezano AC, Lopez RA et al. Can J Cardiol. 2016;32(5):659–68.

  85. 85.

    Tsujita K, Yamanaga K, Komura N, Sakamoto K, Miyazaki T, Ishii M, Tabata N, Akasaka T, Sueta D, Arima Y, Kojima S, Yamamoto E, Yamamuro M, Tanaka T, Izumiya Y, Tayama S, Nakamura S, Kaikita K, Hokimoto S, Ogawa H. Impact of left ventricular hypertrophy on impaired coronary microvascular dysfunction. Int J Cardiol. 2015;187:411–3.

    Article  PubMed  Google Scholar 

  86. 86.

    Petersen SS, Pedersen LR, Pareek M, Nielsen ML, Diederichsen SZ, Leósdóttir M, Nilsson PM, Diederichsen AC, Olsen MH. Factors associated with diagnostic discrepancy for left ventricular hypertrophy between electrocardiography and echocardiography. Blood Press. 2016;23:1–10.

    Google Scholar 

  87. 87.

    Oseni AO, Qureshi WT, Almahmoud MF, Bertoni AG, Bluemke DA, Hundley WG, Lima JA, Herrington DM, Soliman EZ. Left ventricular hypertrophy by ECG versus cardiac MRI as a predictor for heart failure. Heart. 2017;103(1):49–54.

  88. 88.

    Levy D, Labib SB, Anderson KM, Christiansen JC, Kannel WB, Castelli WP. Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation. 1990;81(3):815–20.

    CAS  Article  PubMed  Google Scholar 

  89. 89.

    Kjaer A, Meyer C, Wachtell K, Olsen MH, Ibsen H, Opie L, Holm S, Hesse B. Positron emission tomographic evaluation of regulation of myocardial perfusion in physiological (elite athletes) and pathological (systemic hypertension) left ventricular hypertrophy. Am J Cardiol. 2005 15;96(12):1692–8.

    Article  PubMed  Google Scholar 

  90. 90.

    Poe ND, Eber LM, Norman AS, Selin CE, Terao EN. Myocardial images in nonacute coronary and non coronary heart diseases. J Nucl Med. 1977;18(1):18–23.

    CAS  PubMed  Google Scholar 

  91. 91.

    Hoey ETD, Pakala V, Teoh JK, Simpson H. The role of imaging in hypertensive heart disease. Int J Angiol. 2014;23(2):85–92.

    Article  PubMed  PubMed Central  Google Scholar 

  92. 92.

    Picano E, Palinkas A, Amyot R. Diagnosis of myocardial ischemia in hypertensive patients. J Hypertens. 2001;19(7):1177–83.

    CAS  Article  PubMed  Google Scholar 

  93. 93.

    Bernhardt P, Levenson B, Albrecht A, Engels T, Strohm O. Detection of cardiac small vessel disease by adenosine-stress magnetic resonance. Int J Cardiol. 2007;121(3):261–6.

    Article  PubMed  Google Scholar 

  94. 94.

    Vogel-Claussen J, Skrok J, Dombroski D, Shea SM, Shapiro EP, Bohlman M, Lorenz CH, Lima JA, Bluemke DA. Comprehensive adenosine stress perfusion MRI defines the etiology of chest pain in the emergency room: comparison with nuclear stress test. J Magn Reson Imaging. 2009;30:753–62.

    Article  PubMed  PubMed Central  Google Scholar 

  95. 95.

    Ahn JH, Kim SM, Park SJ, Jeong DS, Woo MA, Jung SH, Lee SC, Park SW, Choe YH, Park PW, Oh JK. Coronary Microvascular dysfunction as a mechanism of angina in severe AS: prospective adenosine-stress CMR study. J Am Coll Cardiol. 2016;67(12):1412–22.

    Article  PubMed  Google Scholar 

  96. 96.

    Yilmaz A, Athanasiadis A, Mahrholdt H, Voehringer M, Ong P, Hill S, Kispert EM, Seebo M, Sechtem U. Diagnostic value of perfusion cardiovascular magnetic resonance in patients with angina pectoris but normal coronary angiograms assessed by intracoronary acetylcholine testing. Heart. 2010;96:372–9.

    Article  PubMed  Google Scholar 

  97. 97.

    Nitenberg A, Pham I, Antony I, Valensi P, Attali JR, Chemla D. Cardiovascular outcome of patients with abnormal coronary vasomotion and normal coronary arteriography is worse in type 2 diabetes mellitus than in arterial hypertension: a 10 year follow-up study. Atherosclerosis. 2005;183:113–20.

    CAS  Article  PubMed  Google Scholar 

  98. 98.

    Nadruz W, Shah AM, Solomon SD. Med Clin North Am. 2017;101(1):7–17.

  99. 99.

    Issa O, Peguero JP, Podesta C et al. J Cardiovasc Echogr. 2017;27(1):1–6.

Download references

Acknowledgements

Not applicable.

Funding

Not applicable.

Availability of data and materials

Not applicable.

Authors’ contributions

SM, responsible for the overall project management, data gathering and co-ordination. Co-authored most sections in the manuscript. VK, VV, responsible for authoring sections regarding echocardiography. MN, GMM, responsible for proofreading, additional suggestions and correction of reviewer comments. GK, AM, team co-ordination, Image collection and processing. All authors read and approved the final manuscript.

Competing interests

Sophie Mavrogeni and Michael Noutsias declare that they serve on the editorial board of BMC Cardiovascular Disorders. Michel Noutsias has been consultant to the IKDT (Institute for Cardiac Diagnosis and Therapy GmbH, Berlin) 2004-2008, and has received honoraria for presentations and/or participated in advisory boards from AstraZeneca, Bayer, Fresenius, Miltenyi Biotech, Novartis, Pfizer and Zoll. Other authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author information

Affiliations

  1. Onassis Cardiac Surgery Center, 50 Esperou Street, 175 61 P.Faliro, Athens, Greece

    Sophie Mavrogeni, Vasiliki Vartela, George Markousis-Mavrogenis & Genovefa Kolovou

  2. Hippokration Hospital, Athens, Greece

    Vasiliki Katsi

  3. Department of Cardiology, Pneumonology and Intensive Care Medicine, Clinic for Internal Medicine I, University Hospital Jena, Friedrich-Schiller-University, Jena, Germany

    Michel Noutsias

  4. Asklipiion Voulas, Athens, Greece

    Athanasios Manolis

Authors
  1. Sophie Mavrogeni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vasiliki Katsi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vasiliki Vartela
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michel Noutsias
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. George Markousis-Mavrogenis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Genovefa Kolovou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Athanasios Manolis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sophie Mavrogeni.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mavrogeni, S., Katsi, V., Vartela, V. et al. The emerging role of Cardiovascular Magnetic Resonance in the evaluation of hypertensive heart disease. BMC Cardiovasc Disord 17, 132 (2017). https://doi.org/10.1186/s12872-017-0556-8

Download citation

Keywords

  • Hypertension
  • Cardiovascular magnetic resonance
  • ECG
  • Echocardiography
  • Coronary angiography

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us